AbbVie, Thermo Fisher Scientific, and Bloom Energy are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that use living organisms and molecular biology techniques to develop drugs, therapies, diagnostics, and research tools. Because these firms typically face long R&D cycles, rigorous regulatory approvals, and binary clinical‐trial outcomes, their stock prices tend to be more volatile and risk-intensive—but they also offer the potential for substantial gains if breakthrough innovations reach the market. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV stock traded up $0.25 during mid-day trading on Monday, hitting $206.94. 2,224,499 shares of the company were exchanged, compared to its average volume of 6,681,529. The company has a market capitalization of $365.57 billion, a PE ratio of 98.49, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66. The firm has a fifty day simple moving average of $191.08 and a 200 day simple moving average of $192.31.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO stock traded up $1.18 during mid-day trading on Monday, hitting $490.19. 641,916 shares of the company were exchanged, compared to its average volume of 2,486,188. The company has a market capitalization of $185.10 billion, a PE ratio of 28.37, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $627.88. The firm has a fifty day simple moving average of $434.83 and a 200 day simple moving average of $459.02.
Read Our Latest Research Report on TMO
Bloom Energy (BE)
Bloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.
NYSE BE traded up $1.55 during trading hours on Monday, reaching $46.83. The company's stock had a trading volume of 5,536,032 shares, compared to its average volume of 7,247,291. The company has a current ratio of 4.99, a quick ratio of 3.21 and a debt-to-equity ratio of 2.18. The business has a 50-day simple moving average of $28.57 and a 200 day simple moving average of $23.54. Bloom Energy has a 52 week low of $9.02 and a 52 week high of $47.21. The stock has a market cap of $10.96 billion, a PE ratio of 1,171.04 and a beta of 3.28.
Read Our Latest Research Report on BE
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access